Renaissance Group LLC Purchases 1,168 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Renaissance Group LLC boosted its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 11.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,523 shares of the company’s stock after buying an additional 1,168 shares during the period. Renaissance Group LLC’s holdings in Medpace were worth $3,828,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of MEDP. Renaissance Technologies LLC boosted its position in shares of Medpace by 12.4% during the 4th quarter. Renaissance Technologies LLC now owns 553,588 shares of the company’s stock valued at $183,919,000 after purchasing an additional 61,100 shares in the last quarter. Invesco Ltd. lifted its stake in Medpace by 91.8% in the fourth quarter. Invesco Ltd. now owns 1,084,753 shares of the company’s stock valued at $360,387,000 after buying an additional 519,186 shares during the period. Quadrant Capital Group LLC lifted its stake in Medpace by 4.2% in the fourth quarter. Quadrant Capital Group LLC now owns 2,287 shares of the company’s stock valued at $760,000 after buying an additional 93 shares during the period. Russell Investments Group Ltd. boosted its holdings in shares of Medpace by 50.6% during the 4th quarter. Russell Investments Group Ltd. now owns 31,531 shares of the company’s stock worth $10,476,000 after buying an additional 10,588 shares in the last quarter. Finally, Envestnet Asset Management Inc. grew its position in shares of Medpace by 2.8% during the 4th quarter. Envestnet Asset Management Inc. now owns 101,727 shares of the company’s stock worth $33,797,000 after buying an additional 2,811 shares during the period. Institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

Shares of NASDAQ MEDP opened at $277.23 on Wednesday. The stock has a market cap of $8.38 billion, a price-to-earnings ratio of 21.95, a PEG ratio of 3.81 and a beta of 1.46. Medpace Holdings, Inc. has a fifty-two week low of $274.02 and a fifty-two week high of $459.77. The firm’s 50-day simple moving average is $327.67 and its 200 day simple moving average is $335.73.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. On average, sell-side analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on MEDP shares. Leerink Partnrs upgraded shares of Medpace to a “hold” rating in a research report on Monday, March 24th. Leerink Partners began coverage on shares of Medpace in a report on Monday, March 24th. They set a “market perform” rating and a $330.00 price objective on the stock. Finally, Robert W. Baird increased their price objective on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Nine analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $376.30.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.